ライフサイエンスコーパス: MAPC

1 MAPC suppression required licensing and proceeded via ID

2 MAPC-SMCs entrapped in fibrin vascular molds became circ

3 MAPCs also induce a shift in macrophages from an M1, or

4 MAPCs are believed to be derived from the bone marrow st

5 MAPCs can be distinguished from MSCs on the basis of cel

6 MAPCs limited donor T-cell proliferation and GVHD-induce

7 MAPCs may therefore be an ideal cell for in vivo therapi

8 MAPCs significantly decrease MMP-9 (matrix metalloprotei

9 MAPCs suppressed T cell proliferation and Th1 and Th17 c

10 MAPCs therefore may constitute a source of cells for tre

11 MAPCs, which can be expanded in vitro and maintained in

12 C57BL /6 MAPCs were infused intravenously into C57BL /6, Rag-2(-/

13 have implications for the use of allogeneic MAPCs and possibly other immunomodulatory nonhematopoiet

14 Among MAPC-derived GFP+CD45.2+ cells in the bone marrow of eng

15 oduced in mice by iliac artery ligation, and MAPCs were administered intramuscularly on day 1.

16 iated recipients given allogeneic marrow and MAPCs; such MAPCs expressed MHC class I antigens in tiss

17 MSCs and MAPCs can be successfully labeled with (18)F-FDG for mol

18 e the successful deployment of both MSCs and MAPCs for the amelioration of human autoimmunity and all

19 ditionally, mice were injected with MSCs and MAPCs prelabeled with (18)F-FDG, and stem cell biodistri

20 Therefore, direct labeling of MSCs and MAPCs with (18)F-FDG is a suitable technique to noninvas

21 As MAPCs proliferate extensively without obvious senescence

22 Because MAPCs can be expanded in culture without obvious senesce

23 Although hematopoietic contribution by MAPCs was comparable to control KTLS HSCs, approximately

24 ely to account for the generation of HSCs by MAPCs.

25 (Flk1(+)) multipotent adult progenitor cell (MAPC) that copurifies with mesenchymal stem cells from p

26 Multipotent adult progenitor cells (MAPCs) are bone marrow-derived stem cells that have exte

27 Multipotent adult progenitor cells (MAPCs) are marrow-derived pluripotent stem cells with a

28 Multipotent adult progenitor cells (MAPCs) are nonhematopoietic stem cells capable of giving

29 und that multipotent adult progenitor cells (MAPCs) can affect both macrophages and dystrophic neuron

30 at human multipotent adult progenitor cells (MAPCs) have the ability to modulate macrophage activatio

31 SCs) and multipotent adult progenitor cells (MAPCs) in vitro with (18)F-FDG and to investigate the po

32 ort that multipotent adult progenitor cells (MAPCs) isolated from rat, murine, porcine, and human bon

33 with multipotential adult progenitor cells (MAPCs) promotes recovery of blood flow through the recru

34 imitive, multipotent adult progenitor cells (MAPCs) that can differentiate into most mesodermal cells

35 lations, multipotent adult progenitor cells (MAPCs), and bone marrow and adipose tissue-derived mesen

36 e termed multipotent adult progenitor cells (MAPCs), can be expanded for >120 population doublings.

37 ate that multipotent adult progenitor cells (MAPCs), isolated from green fluorescent protein (GFP)-tr

38 SCs) and multipotent adult progenitor cells (MAPCs), represent attractive immunomodulatory cell thera

39 t MAPCs would colocalize with donor T cells, MAPCs were injected directly into the spleen at bone mar

40 We demonstrate MAPCs, as well as MSCs, are able to egress from the micr

41 responses and illustrate the requirement for MAPC colocalization to sites of initial donor T-cell act

42 Furthermore, SMCs derived from MAPCs (MAPC-SMCs) demonstrated functional L-type calcium

43 Furthermore, MAPCs favored the proliferation of regulatory T cells du

44 ietic progenitor subsets and functional GFP+ MAPC-derived lymphocytes that were functional.

45 mmune regulatory potential of clinical-grade MAPCs are limited.

46 modulatory characteristics of clinical-grade MAPCs shown in this study suggest that they can be regar

47 tion to assess the ability of clinical-grade MAPCs to control T cell responses that drive immunopatho

48 transplantation into a non-irradiated host, MAPCs engraft and differentiate to the haematopoietic li

49 itive monocytes were significantly higher in MAPC-treated mice than in the control groups at days 3 a

50 10-fold-greater infiltration of monocytes in MAPC-treated than control-treated ischemic limbs at all

51 stribution of flow to microvascular units in MAPC-treated mice.

52 r expansion of microvascular blood volume in MAPC-treated mice than in controls.

53 rily through prostaglandin E(2) synthesis in MAPCs, which resulted in decreased proinflammatory cytok

54 Intravenous MAPCs altered the immune response in the spinal cord and

55 In limb ischemia, MAPCs stimulate the recruitment of proangiogenic monocyt

56 ion and persistence of reporter gene-labeled MAPCs are maximized after intra-arterial delivery or hos

57 To study in vivo biodistribution, we labeled MAPCs with luciferase for sequential quantification of b

58 Mouse (m)MAPCs differentiate into mesenchymal lineage cells as we

59 In addition to these effects on macrophages, MAPCs promote sensory neurite outgrowth, induce sproutin

60 Furthermore, SMCs derived from MAPCs (MAPC-SMCs) demonstrated functional L-type calcium channe

61 In C57BL /6 mice, MAPCs were transiently detected only in the chest compar

62 plants into lethally irradiated C57BL6 mice, MAPCs are of donor origin.

63 rol KTLS HSCs, approximately 10(3)-fold more MAPCs were required for efficient engraftment.

64 Moreover, MAPC-SMCs may lend themselves to tissue engineering appl

65 Moreover, MAPCs altered the balance away from positive and toward

66 ver biodistribution studies revealed that no MAPCs were found in the cord and instead preferentially

67 immunosuppressive capacity and mechanism of MAPC-induced suppression of T-cell alloresponses and ill

68 f SCI, we found that intravenous delivery of MAPCs one day, but not immediately, after SCI significan

69 The origin of MAPCs within bone marrow is unknown.

70 d here multipotent adult progenitor cells or MAPCs--differentiate, at the single cell level, not only

71 all-animal PET experiments with radiolabeled MAPCs and MSCs injected intravenously in mice showed a p

72 Mouse MSCs and rat MAPCs were used for (18)F-FDG uptake kinetics and tracer

73 Human, mouse, and rat MAPCs, cultured on Matrigel with FGF-4 and HGF, differen

74 NK depletion reduced MAPC elimination.

75 en injected into an early blastocyst, single MAPCs contribute to most, if not all, somatic cell types

76 ents given allogeneic marrow and MAPCs; such MAPCs expressed MHC class I antigens in tissues.

77 As such, MAPCs hold promise for tissue injury repair after transp

78 When given systemically, MAPCs did not home to sites of allopriming and did not s

79 These results provide evidence that MAPC-SMCs are phenotypically and functionally similar to

80 Our results demonstrate that MAPCs exert their primary effects in the periphery and p

81 Our results demonstrate that MAPCs have therapeutic benefits after spinal cord injury

82 a-treated cremaster muscle demonstrated that MAPCs migrate to perimicrovascular locations and potenti

83 To ensure that MAPCs would colocalize with donor T cells, MAPCs were in

84 Here, we show that MAPCs can also differentiate into hepatocyte-like cells

85 These responses are sustained beyond the MAPC lifespan, suggesting that paracrine effects promote

86 macrophage activation, and prior exposure to MAPC secreted factors can reduce macrophage-mediated axo

87 monocytes was 10-fold greater in response to MAPC-conditioned than basal media.

88 Optical imaging of luciferase-transfected MAPCs indicated that cells survived for 1 week.

89 y factors that affect adoptively transferred MAPCs.

90 milar to neonatal SMCs and that the in vitro MAPC-SMC differentiation system may be an ideal model fo

91 In vitro, MAPCs cultured with VEGF differentiate into CD34(+), VE-

92 In vitro, MAPCs expressed low levels of major histocompatibility c

93 In vitro, MAPCs potently suppressed allogeneic T-cell activation a

94 B cells, and NK cells contribute to in vivo MAPC rejection.

95 In vivo, MAPCs can differentiate in response to local cues into e

96 the gastrointestinal tract is increased when MAPCs are transplanted in a minimally irradiated host.

97 Widespread MAPC biodistribution and long-term persistence were seen